Clinical Chemistry and Laboratory Medicine

Issue: Feb 2005

Volume 43, Number 2

Hematopoietic cytokines in the sera of patients with pancreatic cancer

Barbara Mroczko,

1. Department of Biochemical Diagnostics, Medical Academy, Bialystok, Poland

1
Maciej Szmitkowski,

2. Department of Biochemical Diagnostics, Medical Academy, Bialystok, Poland

2
Urszula Wereszczyńska-Siemiątkowska,

3. Department of Gastroenterology, Medical Academy, Bialystok, Poland

3
Grażyna Jurkowska

4. Department of Gastroenterology, Medical Academy, Bialystok, Poland

4
Corresponding author: M. Szmitkowski MD, PhD, Department of Biochemical Diagnostics, Medical Academy, M. Skłodowska-Curie 24A, 15-276 Białystok, Poland Phone: +48-85-7468587, Fax: +48-85-7468585,
Citation Information. Clinical Chemical Laboratory Medicine. Volume 43, Issue 2, Pages 146–150, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2005.024, February 2005
Publication History: Received: //; accepted: //; published online: 01/06/2005

Abstract

Hematopoietic cytokines (HCs) can affect the growth and spread of cancer. Therefore, in the present study, we investigated in pancreatic cancer patients the serum levels of selected HCs, such as stem cell factor (SCF), interleukin 3 (IL-3), granulocyte-macrophage-colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF) and macrophage-colony stimulating factor (M-CSF) in relation to a control group and to a group of patients with chronic pancreatitis. Classical tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) were also tested. We compared the serum level of cytokines with the tumor stage. The diagnostic sensitivity, specificity, positive and negative predictive values and receiver-operating characteristics (ROC) curve for cytokines and classical tumor markers were defined. The cytokines were measured in 48 patients with pancreatic cancer, in 23 patients with chronic pancreatitis and in 40 healthy subjects. HCs were determined using ELISA. CEA and CA 19-9 were measured by microparticle enzyme immunoassay. There were significant differences in the levels of circulating SCF, IL-3, GM-CSF, M-CSF, CEA and CA 19-9 in the pancreatic cancer patients compared to the control group. The serum levels of M-CSF and tumor markers were significantly higher in pancreatic cancer patients compared to the pancreatitis group. The levels of SCF, M-CSF and tumor markers were higher in patients with a more advanced tumor stage. The M-CSF serum levels in the pancreatitis group correlated positively with the tumor markers tested – CEA and CA 19-9. The diagnostic sensitivity of SCF and specificity of M-CSF and tumor markers were the highest. The SCF and M-CSF areas under the ROC curve were greater than the areas for other cytokines. These results suggest the potential usefulness of HCs in pancreatic cancer detection; however, further investigations of early-stage pancreatic cancer patients and confirmation by a prospective study are necessary.

Keywords hematopoietic cytokines, pancreatic cancer

Citing Articles

Show All Citing Articles